Replimune Group Inc Market Cap ($762.97 Million)
Market Cap & Net Worth: Replimune Group Inc (REPL)
Replimune Group Inc market cap. Replimune Group Inc (NASDAQ:REPL) has a market capitalization of $762.97 Million ($762.97 Million) as of November 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #9746 globally and #2699 in its home market, demonstrating a 46.87% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Replimune Group Inc's stock price $17.61 by its total outstanding shares 82572619 (82.57 Million). Also see Replimune Group Inc cash flow conversion for how efficiently the company converts equity into cash flow.
Replimune Group Inc Market Cap History (2018–2026)
Replimune Group Inc market cap history from 2018 to 2026. Data shows growth from $825.73 Million to $1.45 Billion (1.82% CAGR). Check Replimune Group Inc stock price for real-time trading data and today's change.
Index Memberships
Replimune Group Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.03% | #279 of 976 |
|
NASDAQ Composite
IXIC
|
$40.09 Trillion | 0.00% | #1035 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.04% | #164 of 263 |
Weight: Replimune Group Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Replimune Group Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Replimune Group Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Replimune Group Inc net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of REPL by Market Capitalization
Companies near Replimune Group Inc in the global market cap rankings as of November 1, 2026. Also see Replimune Group Inc balance sheet assets for a full breakdown of the balance sheet.
Key companies related to Replimune Group Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Replimune Group Inc (2018–2026)
Market capitalization of Replimune Group Inc from 2018 to today. Between 2018 and today, Replimune Group Inc's market cap moved from $825.73 Million to $ 1.45 Billion, with a yearly change of 1.82%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.45 Billion | +81.17% |
| 2025 | $802.61 Million | -19.74% |
| 2024 | $999.95 Million | +43.65% |
| 2023 | $696.09 Million | -69.01% |
| 2022 | $2.25 Billion | +0.37% |
| 2021 | $2.24 Billion | -28.96% |
| 2020 | $3.15 Billion | +165.85% |
| 2019 | $1.18 Billion | +43.50% |
| 2018 | $825.73 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Replimune Group Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $762.97 Million USD |
| MoneyControl | $762.97 Million USD |
| MarketWatch | $762.97 Million USD |
| marketcap.company | $762.97 Million USD |
| Reuters | $762.97 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Replimune Group Inc
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP… Read more